Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...
J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...